| HOME >> BIOLOGY >> TECHNOLOGY |
HUMAN GENOME SCIENCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Three months ended Six months ended
June 30, June 30,
2008 2007 2008 2007
(dollars in thousands, except share
and per share amounts)
Revenue -- R&D contracts $11,567 $9,007 $23,842 $18,270
Costs and expenses:
Research and development(a) 67,455 49,385 140,009 96,564
General and
administrative(b) 14,332 13,159 30,343 25,128
Lease termination and
restructuring credits - (3,673) - (3,673)
Total costs and expenses 81,787 58,871 170,352 118,019
Income (loss) from operations (70,220) (49,864) (146,510) (99,749)
Net investment income
(expense) (3,970) (1,405) (7,114) (2,549)
Gain on sale of long-term
equity investment - - 32,518 -
Income (loss) before taxes (74,190) (51,269) (121,106) (102,298)
Provision for income taxes - - - -
Net income (loss) $(74,190) $(51,269) $(121,106) $(102,298)
Net income (loss) per share,
basic and diluted $(0.55) $(0.38) $(0.90) $(0.76)
Weighted average shares
outstanding,
basic & diluted 135,341,265 134,239,831 135,310,548 134,136,177
(a) Includes stock-based compensation expense of $2,733 ($0.02 per
share) and $3,380 ($0.03 per share) for the three months ended June 30,
2008 and 2007, respectively. Includes stock-based compensation expense of
$5,234 ($0.04 per share) and $6,350 ($0
'/>"/>
| SOURCE Human Genome Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved |